Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.58 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.58 |
| ▸ | KDM1A | O60341 | 10/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.54 |
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | TLR2 | O60603 | 1/20 | 0.52 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25021708 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NPSR1MTNR1AMTNR1BKDM1A | |
| SCHEMBL1600902 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NPSR1MTNR1AMTNR1BKDM1A | |
| SCHEMBL1197466 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NPSR1MTNR1AMTNR1BKDM1A | |
| SCHEMBL13794162 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NPSR1MTNR1AMTNR1BKDM1A | |
| SCHEMBL14544486 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NPSR1MTNR1AMTNR1BKDM1A | |
| Hydrochloric Acid SCHEMBL28254537 | 0.98 | SMN1; SMN2 (0.96) | SMN1; SMN2NPSR1MTNR1AMTNR1BKDM1A | |
| SCHEMBL12539724 | 0.86 | SMN1; SMN2 (0.76) | SMN1; SMN2NPSR1MTNR1AMTNR1BKDM1A | |
| SCHEMBL12539722 | 0.86 | SMN1; SMN2 (0.76) | SMN1; SMN2NPSR1MTNR1AMTNR1BKDM1A | |
| SCHEMBL6154005 | 0.85 | SMN1; SMN2 (0.73) | SMN1; SMN2NPSR1KDM1ACNR1HRH3 | |
| SCHEMBL7980208 | 0.85 | SMN1; SMN2 (0.73) | SMN1; SMN2NPSR1KDM1ACNR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3262036-B1 | THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-9856254-B2 | Alkoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-01-02 | — | — | US | disclosed |
| CN-106488915-A | Cyclopropylamine as LSD1 inhibitor | 因赛特公司 | 2017-03-08 | — | — | CN | disclosed |
| CN-106164066-A | Cyclopropylamines as lsd1 inhibitors | 因赛特公司 | 2016-11-23 | — | — | CN | disclosed |
| US-20160280707-A1 | ALKOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2016-09-29 | — | — | US | disclosed |
| US-20160280707-A1 | ALKOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2016-09-29 | — | — | US | disclosed |
| WO-2016138114-A1 | THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| CN-103857393-B | Cyclopropylamine is as LSD1 inhibitor | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 2016-08-17 | — | — | CN | disclosed |
| US-9365567-B2 | Alkoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2016-06-14 | — | — | US | disclosed |
| US-20090029988-A1 | Hydroxyalkyl Substituted Imidazoquinolines | COLEY PHARMACEUTICAL GROP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090023720-A1 | 2-Amino 1H-Imidazo Ring Systems and Methods | 3M INNOVATIVE PROPERTIES COMPANY | 2009-01-22 | — | — | US | disclosed |
| US-20090023720-A1 | 2-Amino 1H-Imidazo Ring Systems and Methods | 3M INNOVATIVE PROPERTIES COMPANY | 2009-01-22 | — | — | US | disclosed |
| US-20080015184-A1 | Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-01-17 | — | — | US | disclosed |
| US-20080015184-A1 | Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-01-17 | — | — | US | disclosed |
| US-20070259881-A1 | Substituted Imidazo Ring Systems and Methods | COLEY PHARMACEUTICAL GROUP, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070167476-A1 | Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds | 3M INNOVATIVE PROPERTIES COMPANY | 2007-07-19 | — | — | US | disclosed |
| US-20070167476-A1 | Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds | 3M INNOVATIVE PROPERTIES COMPANY | 2007-07-19 | — | — | US | disclosed |
| US-20070060754-A1 | Alkoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-03-15 | — | — | US | disclosed |
| US-20070060754-A1 | Alkoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060754-A1 | Alkoxy substituted imidazoquinolines | IL2, IFNG, IRF3 | SMN1; SMN2 3463/4885NPSR1 4039/4885MTNR1A 1410/4885 |
| US-20070259881-A1 | Substituted Imidazo Ring Systems and Methods | IL2, IL4, IRF3 | SMN1; SMN2 3807/4885NPSR1 3420/4885MTNR1A 776/4885 |
| US-20070167476-A1 | Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds | IL4, IL2, IL5 | SMN1; SMN2 3137/4885NPSR1 1508/4885MTNR1A 760/4885 |
| US-20160280707-A1 | ALKOXY SUBSTITUTED IMIDAZOQUINOLINES | IL2, IFNG, IRF3 | SMN1; SMN2 3463/4885NPSR1 4039/4885MTNR1A 1410/4885 |
| US-20080015184-A1 | Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines | IL2, EIF2AK2, IL4 | SMN1; SMN2 3238/4885NPSR1 4479/4885MTNR1A 2910/4885 |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | SMN1; SMN2 176/4885NPSR1 3059/4885MTNR1A 1615/4885 |
| US-20090023720-A1 | 2-Amino 1H-Imidazo Ring Systems and Methods | IL2, IL2RA, IL4I1 | SMN1; SMN2 2883/4885NPSR1 3338/4885MTNR1A 390/4885 |
| US-20090029988-A1 | Hydroxyalkyl Substituted Imidazoquinolines | IFNG, IRF3, IFNAR1 | SMN1; SMN2 4162/4885NPSR1 4627/4885MTNR1A 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.